WuXi Biologics Reports Record 2025 Annual Results Accessibility StatementSkip Navigation HONG KONG, March 24, 2026 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development and manufacturing, today announced audited results for the year ended December 31, 2025 ("Reporting Period"). Financial Highlights Revenue: Re ...